SCHEMBL6172644

SCHEMBL6172644

CC(c1ccnc(N2CCN(C)CC2)c1)C1(C(C)c2ccnc(N3CCN(C)CC3)c2)NC(=O)N(c2ccc(SC(F)(F)F)cc2)C1=O

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 17/20 0.40
TRPV4 Q9HBA0 1/20 0.39
HRH4 Q9H3N8 2/20 0.35
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6176024 0.92 IGF1R (0.41) IGF1R
SCHEMBL6174968 0.91 ITGB2 (0.39) IGF1R
SCHEMBL6173512 0.91 ADRB1 (0.40) IGF1RHRH4HRH3
SCHEMBL6173502 0.90 IGF1R (0.38) IGF1R
SCHEMBL6172122 0.86 ABL1 (0.46) TRPV4HRH4
SCHEMBL6173419 0.85 IGF1R (0.42) IGF1R
SCHEMBL17558382 0.84 IGF1R (0.39) IGF1R
SCHEMBL6172820 0.83 IGF1R (0.42) IGF1R
SCHEMBL6175683 0.83 IGF1R (0.51) IGF1R
SCHEMBL6174494 0.83 IGF1R (0.42) IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3188729-A1 CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS Genzyme Corporation (US) 2017-07-12 EP disclosed
WO-2016036796-A1 CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS GENZYME CORPORATION (US) 2016-03-10 WO disclosed
EP-1599464-A2 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-11-30 EP disclosed
WO-2004070050-A2 CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-08-19 WO disclosed